Related references
Note: Only part of the references are listed.Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells
Jung-Jin Park et al.
BIOCHEMICAL PHARMACOLOGY (2012)
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Peter J. Hosein et al.
BMC CANCER (2012)
Expanding Surgical Treatment of Pancreatic Cancer The Role of Regional Chemotherapy
Jeremy L. Davis et al.
PANCREAS (2012)
Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?
Jie-Er Ying et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells
Li Lin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Emerging pathways and future targets for the molecular therapy of pancreatic cancer
Vanja Vaccaro et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors
Lauren L. C. Marotta et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
STAT3 SIGNALING: Anticancer Strategies and Challenges
Paul A. Johnston et al.
MOLECULAR INTERVENTIONS (2011)
Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers
Jocelyn Logan-Collins et al.
CANCER RESEARCH (2010)
CHEMOTHERAPY Gemcitabine remains the standard of care for pancreatic cancer
Jordan Berlin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67
Vilppu J. Tuominen et al.
BREAST CANCER RESEARCH (2010)
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
Zhiwei Wang et al.
CANCER RESEARCH (2009)
Pancreatic cancer
Anirban Maitra et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Inhibition of STAT3(Tyr705) phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells
Shujie Zhao et al.
CANCER RESEARCH (2008)
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer
Meredith A. Morgan et al.
CLINICAL CANCER RESEARCH (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity
Khandaker Siddiquee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis
B Schniewind et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines
D DeArmond et al.
ONCOGENE (2003)
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
J Albanell et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
